Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome
Status:
COMPLETED
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study investigated the combined impact of rituximab and targeted nursing care versus tacrolimus and targeted nursing care on efficacy, quality of life, adverse reactions, and recurrence rate in children with challenging (steroid-dependent or frequently relapsing) nephrotic syndrome. Ninety-one pediatric patients were randomized to either receive rituximab plus targeted nursing or tacrolimus plus targeted nursing, and outcomes were assessed over a 6-month period.